triflusal has been researched along with Coronary Restenosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| García, E; Guarinos, J; Ioannidis, K; Larman, M; Moreu, J; Ortas, MR; Piqué, N; Puigfel, B; Rincón, A; Rumoroso, JR; Serra, A; Zueco, JJ | 1 |
| Arumugam, S; Boey, FY; Huang, Y; Mohanty, M; Umashankar, PR; Venkatraman, SS | 1 |
1 trial(s) available for triflusal and Coronary Restenosis
| Article | Year |
|---|---|
Long-term clinical performance of paclitaxel-eluting stents coated with a bioactive polymer (P-5) containing a triflusal derivative: results of the REWAC registry.
Topics: Aged; Coronary Artery Disease; Coronary Restenosis; Drug-Eluting Stents; Female; Humans; Incidence; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Polymers; Prospective Studies; Registries; Salicylates; Thrombosis; Treatment Outcome | 2013 |
1 other study(ies) available for triflusal and Coronary Restenosis
| Article | Year |
|---|---|
The short-term effect on restenosis and thrombosis of a cobalt-chromium stent eluting two drugs in a porcine coronary artery model.
Topics: Animals; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Chromium Alloys; Coronary Restenosis; Coronary Vessels; Disease Models, Animal; Drug Therapy, Combination; Drug-Eluting Stents; Immunosuppressive Agents; Platelet Aggregation Inhibitors; Prosthesis Design; Salicylates; Sirolimus; Swine; Thrombosis; Treatment Outcome | 2009 |